# Zydus Lifesciences (NSE: ZYDUSLIFE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ZYDUSLIFE · Pivot · prices to 21 Oct 2026

Zydus Lifesciences (NSE: ZYDUSLIFE) closed at ₹1,114.00 on 21 Oct 2026, up 0.36% on the day. With a market capitalisation of ₹1,11,272 Cr, it ranks 89th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 22.3× trailing earnings, against a return on equity of 18.6% in FY26. Over the past year the share price has risen 12.2%. Its 52-week range is ₹835.50 (2 Apr 2026) to ₹1,232.10 (29 Sep 2026); the last close is 9.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹7,434 Cr (+18.2% year on year) and net profit ₹1,341 Cr (+7.4%), on a consolidated basis. Promoters held 75.01% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,114.00 |
| Market cap | ₹1,11,272 Cr |
| P/E (trailing) | 22.3 |
| ROE | 18.6% (FY26) |
| ROCE | 20.6% (FY26) |
| Debt to equity | 0.43 |
| 52-week high | ₹1,232.10 (29 Sep 2026) |
| 52-week low | ₹835.50 (2 Apr 2026) |
| 1-year return | +12.2% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹7,434 Cr | +18.2% | ₹1,341 Cr | +7.4% | ₹12.65 |
| Q3 FY26 | ₹6,780 Cr | +32.3% | ₹965 Cr | −3.9% | ₹10.36 |
| Q2 FY26 | ₹6,038 Cr | +18.1% | ₹1,233 Cr | +37.3% | ₹12.51 |
| Q1 FY26 | ₹6,467 Cr | +7.0% | ₹1,487 Cr | +1.6% | ₹14.58 |
| Q4 FY25 | ₹6,290 Cr | +17.2% | ₹1,249 Cr | +1.6% | ₹11.64 |
| Q3 FY25 | ₹5,124 Cr | +13.7% | ₹1,004 Cr | +36.9% | ₹10.17 |
| Q2 FY25 | ₹5,114 Cr | +17.0% | ₹898 Cr | +15.2% | ₹9.06 |
| Q1 FY25 | ₹6,047 Cr | +17.6% | ₹1,464 Cr | +31.6% | ₹14.11 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹23,242 Cr | ₹4,615 Cr |
| FY24 | ₹19,547 Cr | ₹3,854 Cr |
| FY23 | ₹17,237 Cr | ₹1,997 Cr |
| FY22 | ₹15,265 Cr | ₹4,572 Cr |
| FY21 | ₹14,404 Cr | ₹2,138 Cr |
| FY20 | ₹14,253 Cr | ₹1,176 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 75.01%
- Foreign institutions: 6.88%
- Domestic institutions: 11.27%
- Non-institutions: 6.83%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,053.00 | ₹1,10,913 Cr | 124.3 | 8.0% |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,702.50 | ₹1,10,750 Cr | 57 | 20.5% |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,326.60 | ₹1,07,169 Cr | 27.6 | 11.3% |
| [Dr. Reddy's Laboratories](https://app.pivotnow.in/stock/DRREDDY) | ₹1,244.70 | ₹1,03,892 Cr | 25 | 11.1% |
| [Mankind Pharma](https://app.pivotnow.in/stock/MANKIND) | ₹2,254.80 | ₹93,122 Cr | 48.8 | 11.7% |
| [Aurobindo Pharma](https://app.pivotnow.in/stock/AUROPHARMA) | ₹1,616.70 | ₹93,021 Cr | 26.8 | 9.2% |

## Questions and answers

### What is the share price of Zydus Lifesciences today?

Zydus Lifesciences (NSE: ZYDUSLIFE) last closed at ₹1,114.00 on 21 Oct 2026. Its 52-week high is ₹1,232.10 and its 52-week low is ₹835.50.

### What is the market cap of Zydus Lifesciences?

Zydus Lifesciences' market capitalisation is ₹1,11,272 Cr (₹1.11 lakh Cr) at the 21 Oct 2026 close, ranking 89th among the NSE companies Pivot tracks.

### What is the P/E ratio of Zydus Lifesciences?

Zydus Lifesciences trades at a trailing P/E of 22.3. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.8.

### What is the ROE and ROCE of Zydus Lifesciences?

Return on equity was 18.6% in FY26 and return on capital employed was 20.6% in FY26 (consolidated figures).

### Is Zydus Lifesciences a debt-free company?

No. Zydus Lifesciences' debt-to-equity ratio was 0.43 in FY26, with total debt of ₹3,188 Cr.

### What were Zydus Lifesciences' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Zydus Lifesciences reported revenue of ₹7,434 Cr, +18.2% year on year, and net profit of ₹1,341 Cr, +7.4% year on year.

### How has Zydus Lifesciences stock performed over the last year?

Zydus Lifesciences' share price has risen 12.2% over the past year, −2.5% over three months and −3.7% over one month, to the 21 Oct 2026 close.

### What is the shareholding pattern of Zydus Lifesciences?

As of 30 Jun 2026: promoters 75.01%, foreign institutions 6.88%, domestic institutions 11.27%, non-institutions 6.83%.

### Who are Zydus Lifesciences' competitors?

The listed Pharma & Healthcare companies closest to Zydus Lifesciences by market cap are Laurus Labs, Apollo Hospitals Enterprise, Cipla, Dr. Reddy's Laboratories, Mankind Pharma and Aurobindo Pharma.

### Is Zydus Lifesciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Zydus Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ZYDUSLIFE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.